In this episode of Behind the Bell, Skye Bioscience CEO Punit Dhillon reflects on the clinical-stage biotechnology company’s mission and how being #NasdaqListed helps them to deliver on that mission.

Watch more of Behind the Bell on Nasdaq.com: https://www.nasdaq.com/news-and-insig...